The possibility of using the status of HPV, p53, and miRNAs as biomarkers for the selection of therapy, as well as updating the interest in tumor metabolism and, in particular, the Warburg effect as a possible target involving the restoration of p53 function and implicitly the net benefit in the therapeutic response. The gene discussed is TP53; the disease is neoplasm.